uniQure Announces Pricing of its Public Offering
September 05 2019 - 8:39PM
uniQure N.V. (Nasdaq: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe unmet
medical needs today announced the pricing of its underwritten
public offering of 4,891,305 of its ordinary shares at a
public offering price of $46.00 per share. The gross proceeds to
uniQure from the offering, before deducting the underwriting
discounts and commissions and estimated offering expenses payable
by uniQure, are expected to be approximately $225 million. All
ordinary shares to be sold in the offering are being sold by
uniQure. In addition, uniQure has granted to the underwriters a
30-day option to purchase up to 733,695 additional ordinary
shares at the public offering price, less underwriting discounts
and commissions. The offering is expected to close on or about
September 10, 2019, subject to the satisfaction of customary
closing conditions.
Goldman Sachs & Co. LLC and SVB Leerink are
acting as joint book-running managers for the offering. Stifel is
also acting as a book-running manager for the offering. Cantor
Fitzgerald & Co. and SunTrust Robinson Humphrey are acting as
co-lead managers and H.C. Wainwright & Co. is acting as the
co-manager for the offering.
The securities described above are being offered
by uniQure pursuant to its automatically effective shelf
registration statement on Form S-3 (File No. 333-225636) filed with
the Securities Exchange Commission (the “SEC”) on June 14,
2018. A preliminary prospectus supplement and accompanying
prospectus relating to the offering was filed with the SEC and a
final prospectus supplement and the accompanying prospectus
relating to this offering will be filed with the SEC. The
preliminary prospectus supplement and accompanying prospectus is
available, and the final prospectus supplement and accompanying
prospectus will be available, for free on the SEC’s website at
http://www.sec.gov. When available, copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from Goldman Sachs & Co. LLC,
Prospectus Department, 200 West Street, New York, NY 10282,
telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com, SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525 ext. 6132 or by email at
syndicate@svbleerink.com, and Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite
3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by
email at syndprospectus@stifel.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities, in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer,
if at all, will be made only by means of the prospectus supplement
and accompanying prospectus forming a part of the effective
registration statement.
About uniQure
uniQure is delivering on the promise of gene
therapy - single treatments with potentially curative results. We
are leveraging our modular and validated technology platform to
rapidly advance a pipeline of proprietary gene therapies to treat
patients with hemophilia B, hemophilia A, Huntington’s disease,
Fabry disease, spinocerebellar ataxia Type 3 and other
diseases.
Forward-Looking Statement
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements include, without limitation,
statements regarding our expectations of market conditions, the
satisfaction of customary closing conditions related to the public
offering, and other statements including the words “may,” “will,”
“intend,” and similar expressions (as well as other words or
expressions referencing future events, conditions or
circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including: the uncertainties related
to market conditions and the completion of the public offering on
the anticipated terms, or at all, continued interest in our rare
disease portfolio, the ability to develop our product candidates
and technologies, the impact of changes in the financial markets
and global economic conditions, and other risks as are set forth in
uniQure’s Quarterly Report on Form 10-Q filed with the SEC on July
29, 2019. uniQure undertakes no obligations to make any revisions
to the forward-looking statements contained in this release or to
update them to reflect events or circumstances occurring after the
date of this release, whether as a result of new information,
future developments or otherwise.
uniQure Contacts
For
Investors:
For Media:
Maria
Cantor
Eva M. Mulder
Tom MaloneDirect : +339-970-7536
Direct: +31 20 240
6103
Direct: 339-970-7758Mobile: 617-680-9452
Mobile: +31
6 52 33 15 79
Mobile:
339-223-8541m.cantor@uniQure.com
e.mulder@uniQure.com
t.malone@uniqure.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024